3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
57
Breast Neoplasms
35
Neoplasms
32
Parkinson Disease 4, Autosomal Dominant Lewy Body
25
Multiple Myeloma
24
Leukemia, Myeloid, Acute
21
Recurrence
19
Neoplasm Metastasis
17
Colorectal Neoplasms
17
Ovarian Neoplasms
15
Lymphoma, Non-Hodgkin
15
Melanoma
14
Leukemia, Lymphocytic, Chronic, B-Cell
14
Carcinoma, Renal Cell
14
Leukemia
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Lymphoma, Follicular
12
Urinary Bladder Neoplasms
11
Myelodysplastic Syndromes
11
Lung Neoplasms
11
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
10
Hematologic Neoplasms
10
Carcinoma, Hepatocellular
10
Stomach Neoplasms
9
Prostatic Neoplasms
9
Lymphoma, Mantle-Cell
9
Lymphoma, Large B-Cell, Diffuse
9
Lymphoma
9
Adenocarcinoma
9
Thyroid Neoplasms
8
Interventions
ribociclib
1
Tamoxifen
1
Letrozole
1
Goserelin
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Has announcements
×
Advanced Metastatic Breast Cancer
×
Clear all
NCT02278120
2024-03-12
MONALEESA-7
Novartis
Phase 3
Completed
672 enrolled
16 charts
1 FDA